Selected trials utilizing brentuximab vedotin in frontline therapy
| Regimen . | N . | Median follow-up (months) . | ORR/CR . | PFS . | Reference . |
|---|---|---|---|---|---|
| Advanced Stage | |||||
| ECHELON-1 BV-AVDx6 ABVDx6 | 1334 | 73 | BV-AVD: 86% ORR ABVD: 83% ORR | 5-year: 82.2% BV-AVD 5-year: 75.3% ABVD | Ansell et al N Engl J Med 2022 |
| HD21 escBx4-6 BrECADDx4-6 | 1500 | 40 | escB: 80% CR BrECADD: 82% CR | 3-year: 92.3% escB 3-year: 94.9% BrECADD | Borchmann et al Lancet 2024 |
| Early-stage | |||||
| BREACH BV-AVDx4 + 30 Gy INRT ABVDx4 + 30 Gy INRT | 170 | 45 | BV-AVD: 87.6% CR (8% missing data) ABVD: 77.2% CR (19% missing data) | 2-year: 97.3% BV-AVD 2-year: 92.6% ABVD | Fornecker et al J Clin Oncol 2023 |
| BV-AVDx4 +/- RT | 117 | 46 | 96% CR | 2-year: 94% | Kumar et al J Clin Oncol 2021 |
| BV-AVD × 4-6 Interim PET adapted | 34 | 14 | 88% CR | 14-month: 90% | Abramson et al JCO 2015 (abstract) |
| BV-ADx4-6 Interim PET adapted | 34 | 53 | 97% CR | 5-year: 91% | Abramson et al Blood Advances 2023 |
| ABVDx2-6, BV × 6 Interim PET adapted | 41 | 47 | 95% CR | 3-year: 92% | Park et al Blood Advances 2020 |
| Elderly or anthracycline-ineligible | |||||
| Sequential BV-AVD | 48 | 23 | 95% ORR 93% CR | 2-year: 84% | Evens et al J Clin Oncol 2018 |
| BV-nivolumab | 21 | 51.6 | 86% ORR 67% CR | Not reached | Friedberg et al Blood 2024 |
| Regimen . | N . | Median follow-up (months) . | ORR/CR . | PFS . | Reference . |
|---|---|---|---|---|---|
| Advanced Stage | |||||
| ECHELON-1 BV-AVDx6 ABVDx6 | 1334 | 73 | BV-AVD: 86% ORR ABVD: 83% ORR | 5-year: 82.2% BV-AVD 5-year: 75.3% ABVD | Ansell et al N Engl J Med 2022 |
| HD21 escBx4-6 BrECADDx4-6 | 1500 | 40 | escB: 80% CR BrECADD: 82% CR | 3-year: 92.3% escB 3-year: 94.9% BrECADD | Borchmann et al Lancet 2024 |
| Early-stage | |||||
| BREACH BV-AVDx4 + 30 Gy INRT ABVDx4 + 30 Gy INRT | 170 | 45 | BV-AVD: 87.6% CR (8% missing data) ABVD: 77.2% CR (19% missing data) | 2-year: 97.3% BV-AVD 2-year: 92.6% ABVD | Fornecker et al J Clin Oncol 2023 |
| BV-AVDx4 +/- RT | 117 | 46 | 96% CR | 2-year: 94% | Kumar et al J Clin Oncol 2021 |
| BV-AVD × 4-6 Interim PET adapted | 34 | 14 | 88% CR | 14-month: 90% | Abramson et al JCO 2015 (abstract) |
| BV-ADx4-6 Interim PET adapted | 34 | 53 | 97% CR | 5-year: 91% | Abramson et al Blood Advances 2023 |
| ABVDx2-6, BV × 6 Interim PET adapted | 41 | 47 | 95% CR | 3-year: 92% | Park et al Blood Advances 2020 |
| Elderly or anthracycline-ineligible | |||||
| Sequential BV-AVD | 48 | 23 | 95% ORR 93% CR | 2-year: 84% | Evens et al J Clin Oncol 2018 |
| BV-nivolumab | 21 | 51.6 | 86% ORR 67% CR | Not reached | Friedberg et al Blood 2024 |